Elevated plasma F2-isoprostane levels in schizophrenia.
Schizophrenia is one of the most disabling psychiatric disorders with increased morbidity and mortality. Both schizophrenia and oxidative stress have been associated with accelerated aging. Previous studies found increased oxidative stress in individuals with schizophrenia, though only one study measured F2-isoprostanes and did so in urine. To our knowledge, the present study is the first to assess plasma F2-isoprostane levels, the putative gold standard measure of systemic oxidative stress in vivo, in schizophrenia.



We compared plasma F2-isoprostane levels in 134 stable outpatients with schizophrenia and 120 age- and gender-matched healthy comparison (HC) subjects. Sociodemographic and clinical data were collected in both groups.



Plasma F2-isoprostane levels were significantly higher in the schizophrenia group than in the HC group. Women had higher F2-isoprostane levels compared to men, and those with higher body mass index (BMI) had higher levels, within each group. F2-isoprostane levels correlated with BMI, physical functioning, and medical comorbidity but not with severity of psychopathology or executive function. Linear models showed significant effects of diagnosis, gender, and BMI on F2-isoprostane levels, but no interactions.



Our finding of increased oxidative stress in schizophrenia is consistent with reports of increased morbidity and mortality as well as accelerated aging in schizophrenia. The significant associations between F2-isoprostane levels and both gender and BMI warrant further study.
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.
Ellen E
EE
Lee
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Desert-Pacific Mental Illness Research Education and Clinical Center, Veterans Affairs San Diego Healthcare System, San Diego, United States.
Lisa T
LT
Eyler
Department of Psychiatry, University of California, San Francisco, United States.
Owen M
OM
Wolkowitz
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, United States.
Averria Sirkin
AS
Martin
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, United States.
Chase
C
Reuter
Department of Psychiatry, Stanford University, Palo Alto, United States.
Helena
H
Kraemer
Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, United States; Center for Healthy Aging, University of California San Diego, La Jolla, CA, United States; Department of Neurosciences, University of California, San Diego, United States. Electronic address: djeste@ucsd.edu.
Dilip V
DV
Jeste
D000328:Adult; D000368:Aged; D000375:Aging / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology; D011618:Psychotic Disorders / Q000097:blood*; D012559:Schizophrenia / Q000097:blood*
D015415:Biomarkers; D028441:F2-Isoprostanes
Aging; Body mass index; F2-isoprostanes; Gender; Oxidative stress; Schizophrenia